chemXplore tracks 22 projects in Denmark, of which 6 are active.
Of the active ones, 3 new construction and 3 expansion.
2 active projects carry no start-up date yet. The dates themselves, per project, are for subscribers.
EU clears first PD‑1 inhibitor plus ADC regimen for resectable muscle‑invasive bladder cancer regardless of cisplatin eligibility; phase 3 showed EFS HR 0.53 and OS HR 0.65.
Converts excess shore crabs via chemical-free mechanical/thermal separation into aquafeed and pet-food proteins and shell-derived chitosan; pilot 2 t/day, target 40,000 t/yr.
Q3 revenue rose >10% y/y and company remains on track for ~15–16% full‑year growth; Q3 net cash usage ≈ $28M with ≈ $134M cash on hand; margin improvement and an ~$8bn electrolyzer pipeline.
Selected for a six‑month incubation to test a modular carbon capture unit designed for space‑constrained data centre power plants.
Rina‑S 120 mg/m² Q3W achieved 45.9% ORR and 12.1‑month median DOR in 109 platinum‑resistant ovarian cancer patients; activity seen across FRα expression levels.
Preferred electrolyzer supplier for over 1 GW of e‑SAF projects; initial 280 MW GenEco will produce ~110 t/day renewable H2 for jet fuel at Port of Vordingborg; ENDOR moving to FID.
€1bn Europe-wide auction for industrial process-heat decarbonisation; bidding opens early Dec 2026. Supports electrification, renewable heat and SMRs with a fixed premium per tCO2.
40,000 t/yr eSAF commitment for 10+ years from Project Endor in Denmark; deliveries planned from early 2030s; fuel claims up to 98% lifecycle emissions reduction and EU compliance.
Greensand begins commercial offshore CO₂ storage from biogenic sources, using a dedicated terminal and the EU’s first purpose-built CO₂ carrier to inject into a depleted North Sea reservoir.
SAF reached 1.1 Mt (2.8% share), a near sixfold rise from 2024; supplied at 121 airports, 84% produced in the EU, and 18 Member States host production projects.
